BR112017024783A2 - composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais - Google Patents
composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colateraisInfo
- Publication number
- BR112017024783A2 BR112017024783A2 BR112017024783A BR112017024783A BR112017024783A2 BR 112017024783 A2 BR112017024783 A2 BR 112017024783A2 BR 112017024783 A BR112017024783 A BR 112017024783A BR 112017024783 A BR112017024783 A BR 112017024783A BR 112017024783 A2 BR112017024783 A2 BR 112017024783A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- progestin
- shbg
- side effects
- modulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
são divulgados composições e métodos para a administração de hormônios de progestina que têm afinidade de ligação à globulina ligadora dos hormônios sexuais (shbg). as composições combinam tais progestinas com ligantes de shbg não progestina, para deslocar pelo menos parte da progestina da shbg no plasma sanguíneo, aumentando assim a sua biodisponibilidade. também são divulgados métodos para modular os níveis de progestina e estrogênio no sangue através do uso de ligação e deslocamento da shbg, para otimizar a eficácia das formulações para contracepção e minimizar os efeitos colaterais e eventos adversos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562163113P | 2015-05-18 | 2015-05-18 | |
US201562254999P | 2015-11-13 | 2015-11-13 | |
PCT/US2016/033024 WO2016187269A1 (en) | 2015-05-18 | 2016-05-18 | Contraceptive compositions and methods for improved efficacy and modulation of side effects |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017024783A2 true BR112017024783A2 (pt) | 2018-08-07 |
Family
ID=56116539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017024783A BR112017024783A2 (pt) | 2015-05-18 | 2016-05-18 | composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180125860A1 (pt) |
EP (1) | EP3297634A1 (pt) |
JP (2) | JP2018515552A (pt) |
CN (1) | CN107995864A (pt) |
AU (2) | AU2016264137B2 (pt) |
BR (1) | BR112017024783A2 (pt) |
CA (1) | CA2986039A1 (pt) |
HK (1) | HK1251938A1 (pt) |
MX (1) | MX2017014768A (pt) |
WO (1) | WO2016187269A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
AU2016280863B2 (en) | 2015-06-18 | 2021-04-01 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
KR102662025B1 (ko) | 2015-06-18 | 2024-05-02 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
RS61812B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetriol |
MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
AU2018235778B2 (en) * | 2017-03-15 | 2024-04-18 | Agile Therapeutics, Inc. | Personalized contraceptive formulations |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
IE61236B1 (en) * | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
US4863738A (en) | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US7704983B1 (en) * | 1992-03-02 | 2010-04-27 | Eastern Virginia Medical School | Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception |
MX9301121A (es) * | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
US5552394A (en) * | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
CN1188189C (zh) | 1995-06-07 | 2005-02-09 | 奥瑟-麦内尔制药公司 | 基质层含有17-脱乙酰基诺孕酯的经皮贴片及基质的用途 |
US6139873A (en) * | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
US6251956B1 (en) * | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US7045145B1 (en) | 1999-11-24 | 2006-05-16 | Agile Therapeutics, Inc. | Transdermal contraceptive delivery system and process |
DE60143360D1 (de) | 2000-08-03 | 2010-12-09 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert |
JP4965263B2 (ja) * | 2003-12-12 | 2012-07-04 | バイエル ファーマ アクチエンゲゼルシャフト | 浸透増強剤を必要としないホルモンの経皮送達 |
CN1672685A (zh) * | 2004-03-26 | 2005-09-28 | 董可娟 | 一种新的避孕药物 |
US20100178323A1 (en) * | 2007-07-10 | 2010-07-15 | Agis Kydonieus | Dermal Delivery Device |
ES2494853T3 (es) * | 2007-11-02 | 2014-09-16 | Acrux Dds Pty Ltd | Sistema de administración transdérmica |
WO2010042610A1 (en) * | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
WO2010042612A1 (en) * | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
US9198876B2 (en) * | 2008-10-08 | 2015-12-01 | Agile Therapeutics, Inc. | Contraceptive transdermal delivery of hormones |
WO2010111488A1 (en) * | 2009-03-27 | 2010-09-30 | Agile Therapeutics, Inc. | Transdermal delivery |
CA2861324A1 (en) | 2012-01-27 | 2013-08-01 | Agile Therapeutics, Inc. | Transdermal hormone delivery |
EP2934497B1 (en) * | 2012-12-21 | 2016-11-23 | Teikoku Pharma USA, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
-
2016
- 2016-05-18 CA CA2986039A patent/CA2986039A1/en active Pending
- 2016-05-18 MX MX2017014768A patent/MX2017014768A/es unknown
- 2016-05-18 EP EP16728152.6A patent/EP3297634A1/en active Pending
- 2016-05-18 AU AU2016264137A patent/AU2016264137B2/en active Active
- 2016-05-18 JP JP2017560243A patent/JP2018515552A/ja active Pending
- 2016-05-18 WO PCT/US2016/033024 patent/WO2016187269A1/en active Application Filing
- 2016-05-18 US US15/574,698 patent/US20180125860A1/en not_active Abandoned
- 2016-05-18 BR BR112017024783A patent/BR112017024783A2/pt not_active Application Discontinuation
- 2016-05-18 CN CN201680029116.5A patent/CN107995864A/zh active Pending
-
2018
- 2018-09-03 HK HK18111267.3A patent/HK1251938A1/zh unknown
-
2021
- 2021-07-15 JP JP2021117119A patent/JP2021169503A/ja active Pending
- 2021-11-08 AU AU2021262853A patent/AU2021262853B2/en active Active
-
2023
- 2023-08-22 US US18/236,839 patent/US20240156838A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016187269A1 (en) | 2016-11-24 |
JP2018515552A (ja) | 2018-06-14 |
US20180125860A1 (en) | 2018-05-10 |
AU2021262853A1 (en) | 2021-12-02 |
AU2016264137A1 (en) | 2018-01-18 |
MX2017014768A (es) | 2018-03-23 |
EP3297634A1 (en) | 2018-03-28 |
AU2016264137B2 (en) | 2021-08-19 |
JP2021169503A (ja) | 2021-10-28 |
AU2021262853B2 (en) | 2024-05-09 |
US20240156838A1 (en) | 2024-05-16 |
HK1251938A1 (zh) | 2019-05-03 |
CA2986039A1 (en) | 2016-11-24 |
CN107995864A (zh) | 2018-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017024783A2 (pt) | composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais | |
CL2020002024A1 (es) | Moduladores de calpaínas y usos terapeuticos de los mismos. (divisional solicitud 201900793) | |
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
CL2017001364A1 (es) | Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos. | |
WO2018083087A3 (en) | Binding proteins | |
MY190855A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
BR112018073739A2 (pt) | proteína de ligação de albumina sérica de domínio único | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
BR112017028517A2 (pt) | ?composição farmacêutica, vetor, peptídeo, polinucleotídeo e conjugado isolado e composição? | |
BR112018009437A2 (pt) | controle de níveis de oxirredução celular | |
WO2017100700A3 (en) | Peptides for renal therapy | |
MX2019003099A (es) | Composicion farmaceutica. | |
EP3706774A4 (en) | GLP-2 ANALOGUES AND PEPTIBODIES FOR USE BEFORE, DURING OR AFTER SURGICAL PROCEDURE | |
BR112015017246A2 (pt) | formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel | |
NI201700173A (es) | Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso | |
MX2021006969A (es) | Ligante peptidico. | |
BR112016005252A2 (pt) | composto direcionado às proteínas poliposi coli adematosa (apc) truncadas, uso do mesmo e célula epitelial do cólon humana imortalizada (hcec) | |
BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
ZA202006377B (en) | Boronic acid derivatives and therapeutic uses thereof | |
SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
BR112022012205A2 (pt) | Compostos ativos para receptores nucleares | |
AR113453A1 (es) | Concentrados acuosos en suspensión a base de 2-[(2,4-diclorofenil)-metil]-4,4-dimetil-3-isoxazolidinonas | |
MX2021010022A (es) | Composicion farmaceutica. | |
WO2015100370A3 (en) | Sustained release depot formulations of therapeutic proteins, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |